The shelf effectiveness, combined with two active resale registrations from creditors, signals persistent dilution pressure. Monitor for any takedown announcements under the shelf or further conversions by Perceptive/YA II — each conversion at a discount to market will pressure TRIB shares. The cross-filing context (F-1 registrations + debt overhang) amplifies the bearish read-through.
Price Chart
Executive Summary
The SEC declared effective Trinity Biotech's F-3 shelf registration (File No. 333-295842) on May 22, 2026, enabling the company to sell securities on a delayed or continuous basis. This follows prior F-1 registrations for resale of up to 55.9M ADSs by Perceptive Credit Holdings, and a separate F-1 for up to 35.3M ADSs under a Standby Equity Purchase Agreement with YA II PN, Ltd. The shelf activation creates ongoing dilution overhang for a micro-cap company already under Nasdaq compliance review with $134.58M in debt.
Key Facts
- Effectiveness date: May 22, 2026 for F-3 shelf registration (File No. 333-295842)
- Prior F-1 (Jan 15, 2026) registers up to 55,890,900 ADSs (1,117,818,000 ordinary shares) for resale by Perceptive Credit Holdings, convertible from $60M note at 97% of VWAP with a $1.03 floor
- Prior F-1 (Feb 25, 2026) registers up to 35.3M ADSs for resale by YA II PN, Ltd. under Standby Equity Purchase Agreement, allowing up to $25M in sales at market discount over 3 years
- Company has $134.58M in debt and is under Nasdaq compliance review for low bid price and market value
- Market cap is approximately $12M, making dilution from these registrations highly material
Financial Impact
Combined potential dilution from up to 91.2M ADSs (55.9M + 35.3M) against a $12M market cap; existing $60M convertible note and $25M standby equity facility create severe dilution risk
Risk Factors
- Massive dilution from up to 91.2M ADSs registered for resale relative to $12M market cap
- Convertible note conversions at 97% of VWAP with $1.03 floor create persistent selling pressure
- Nasdaq compliance risk for low bid price and market value could lead to delisting
- Debt of $134.58M far exceeds market cap, raising solvency concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001746 |
| Document: 9999999995-26-001746-index.html | 9999999995-26-001746 |
| Document: 9999999995-26-001746.txt | 9999999995-26-001746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers